Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC-MS/MS

被引:8
作者
Zhou, Yunfang [2 ]
Wang, Shuanghu [2 ]
Ding, Ting [2 ]
Wu, Mingdong [2 ]
Geng, Peiwu [2 ]
Zhang, Qingwei [3 ]
Ma, Jianshe [1 ]
机构
[1] Wenzhou Med Univ, Funct Expt Teaching Ctr, Wenzhou, Peoples R China
[2] Wenzhou Med Univ, Peoples Hosp Lishui City, Lab Clin Pharm, Lishui, Peoples R China
[3] Shanghai Inst Pharmaceut Ind, Shanghai, Peoples R China
关键词
Dasatinib; imatinib; interaction; pharmacokinetic; rat; CHRONIC MYELOID-LEUKEMIA; CHROMATOGRAPHY-MASS-SPECTROMETRY; BCR-ABL; PLASMA; RESISTANCE; KINASE; BMS-354825; INHIBITOR; MESYLATE; EFFICACY;
D O I
10.3109/03639045.2015.1004182
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study examined whether oral administration of dasatinib to the rats with imatinib led to any pharmacokinetic interactions. Twenty-four rats were divided randomly into three groups, imatinib group (imatinib 25mg/kg, n=8), dasatinib group (dasatinib 15mg/kg, n=8) and co-administration group (dasatinib 15mg/kg and imatinib 25mg/kg, n=8). The concentration of imatinib and dasatinib in rat plasma was determined by a sensitive and simple UPLC-MS/MS method. There was statistical pharmacokinetics difference for imatinib in the imatinib group and co-administration group, when co-oral administration imatinib with dasatinib, MRT(0-t) increased (p<0.01). There was statistical pharmacokinetics difference for dasatinib in the dasatinib group and co-administration group, when co-oral administration dasatinib with imatinib, C-max and AUC increased (p<0.01), CL and V decreased (p<0.01). These data indicate dasatinib could slightly influence the pharmacokinetic profile of imatinib in rats, and imatinib could influence the pharmacokinetic profile of dasatinib in rats, which might cause drug-drug interactions when using imatinib with dasatinib.
引用
收藏
页码:1948 / 1953
页数:6
相关论文
共 36 条
[1]   Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].
Antonescu, CR ;
Besmer, P ;
Guo, TH ;
Arkun, K ;
Hom, G ;
Koryotowski, B ;
Leversha, MA ;
Jeffrey, PD ;
Desantis, D ;
Singer, S ;
Brennan, MF ;
Maki, RG ;
DeMatteo, RP .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190
[2]  
BEDI A, 1994, BLOOD, V83, P2038
[3]   Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations [J].
Bradeen, Heather A. ;
Eide, Christopher A. ;
O'Hare, Thomas ;
Johnson, Kara J. ;
Willis, Stephanie G. ;
Lee, Francis Y. ;
Druker, Brian J. ;
Deininger, Michael W. .
BLOOD, 2006, 108 (07) :2332-2338
[4]   Determination of Rhynchophylline in Rat Plasma by Liquid Chromatography Mass Spectrometry and Its Application [J].
Cai, Jinzhang ;
Lin, Chongliang ;
Ma, Jianshe ;
Hu, Lufeng ;
Lin, Guanyang ;
Wang, Xianqin .
JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2014, 52 (07) :661-665
[5]   Metabolism and disposition of dasatinib after oral administration to humans [J].
Christopher, Lisa J. ;
Cui, Donghui ;
Wu, Chiyuan ;
Luo, Roger ;
Manning, James A. ;
Bonacorsi, Samuel J. ;
Lago, Michael ;
Allentoff, Alban ;
Lee, Francis Y. F. ;
McCann, Betty ;
Galbraith, Susan ;
Reitberg, Donald P. ;
He, Kan ;
Barros, Anthony, Jr. ;
Blackwood-Chirchir, Anne ;
Humphreys, W. Griffith ;
Iyer, Ramaswamy A. .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (07) :1357-1364
[6]   Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].
de Lavallade, Hugues ;
Apperley, Jane F. ;
Khorashad, Jamshid S. ;
Milojkovic, Dragana ;
Reid, Alistair G. ;
Bua, Marco ;
Szydlo, Richard ;
Olavarria, Eduardo ;
Kaeda, Jaspal ;
Goldman, John M. ;
Marin, David .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363
[7]   The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].
Deininger, M ;
Buchdunger, E ;
Druker, BJ .
BLOOD, 2005, 105 (07) :2640-2653
[8]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[9]   A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study [J].
Gershkovich, Pavel ;
Ibrahim, Fady ;
Sivak, Olena ;
Darlington, Jerald W. ;
Wasan, Kishor M. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2014, 40 (03) :338-344
[10]   Dasatinib as first-line therapy for CML-CP [J].
Gilbert, Judith A. .
LANCET ONCOLOGY, 2014, 15 (01) :E7-E7